| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8318706 | ALMIRALL | Substituted tetracycline compounds |
May, 2031
(7 years from now) | |
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9481639 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Aug, 2028
(4 years from now) | |
| US8513223 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Dec, 2029
(5 years from now) | |
Seysara is owned by Almirall.
Seysara contains Sarecycline Hydrochloride.
Seysara has a total of 4 drug patents out of which 0 drug patents have expired.
Seysara was authorised for market use on 01 October, 2018.
Seysara is available in tablet;oral dosage forms.
Seysara can be used as a method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride crystalline salt, a method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses, a method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride, a method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sarecycline hydrochloride.
Drug patent challenges can be filed against Seysara from 01 October, 2022.
The generics of Seysara are possible to be released after 09 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg...
Dosage: TABLET;ORAL
SEYSARA family patents
